JP6660877B2 - アミロイド−β−結合性ペプチド、ならびにアルツハイマー型認知症の治療および診断のためのその使用 - Google Patents

アミロイド−β−結合性ペプチド、ならびにアルツハイマー型認知症の治療および診断のためのその使用 Download PDF

Info

Publication number
JP6660877B2
JP6660877B2 JP2016517288A JP2016517288A JP6660877B2 JP 6660877 B2 JP6660877 B2 JP 6660877B2 JP 2016517288 A JP2016517288 A JP 2016517288A JP 2016517288 A JP2016517288 A JP 2016517288A JP 6660877 B2 JP6660877 B2 JP 6660877B2
Authority
JP
Japan
Prior art keywords
peptide
amyloid
seq
peptide according
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016517288A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016539911A5 (https=
JP2016539911A (ja
Inventor
ヴィルボルト・ディーター
Original Assignee
フォルシュングスツェントルム・ユーリッヒ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102013016002.2A external-priority patent/DE102013016002A1/de
Priority claimed from DE102014003262.0A external-priority patent/DE102014003262A1/de
Application filed by フォルシュングスツェントルム・ユーリッヒ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング filed Critical フォルシュングスツェントルム・ユーリッヒ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング
Publication of JP2016539911A publication Critical patent/JP2016539911A/ja
Publication of JP2016539911A5 publication Critical patent/JP2016539911A5/ja
Application granted granted Critical
Publication of JP6660877B2 publication Critical patent/JP6660877B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016517288A 2013-09-26 2014-09-23 アミロイド−β−結合性ペプチド、ならびにアルツハイマー型認知症の治療および診断のためのその使用 Active JP6660877B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE102013016002.2 2013-09-26
DE102013016002.2A DE102013016002A1 (de) 2013-09-26 2013-09-26 Zyklische, Amyloid-Beta-bindende Peptide und deren Verwendung
DE102014003262.0A DE102014003262A1 (de) 2014-03-12 2014-03-12 Amyloid-Beta-bindende Peptide und deren Verwendung für die Therapie und die Diagnose der Alzheimerschen Demenz
DE102014003262.0 2014-03-12
PCT/DE2014/000477 WO2015043567A1 (de) 2013-09-26 2014-09-23 Amyloid-beta-bindende peptide und deren verwendung für die therapie und die diagnose der alzheimerschen demenz

Publications (3)

Publication Number Publication Date
JP2016539911A JP2016539911A (ja) 2016-12-22
JP2016539911A5 JP2016539911A5 (https=) 2018-12-27
JP6660877B2 true JP6660877B2 (ja) 2020-03-11

Family

ID=51932152

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016517288A Active JP6660877B2 (ja) 2013-09-26 2014-09-23 アミロイド−β−結合性ペプチド、ならびにアルツハイマー型認知症の治療および診断のためのその使用

Country Status (7)

Country Link
US (2) US10995118B2 (https=)
EP (2) EP3747454B9 (https=)
JP (1) JP6660877B2 (https=)
CN (1) CN105745219B (https=)
DK (1) DK3049099T3 (https=)
ES (2) ES2818929T3 (https=)
WO (1) WO2015043567A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102016125645A1 (de) 2016-12-23 2018-06-28 Forschungszentrum Jülich GmbH D-enantiomere Peptide zur Therapie von chronischem und neuropathischem Schmerz
CN106866792B (zh) * 2017-02-24 2020-09-04 中山大学 一类环十肽分子及其应用
DE102017010842A1 (de) * 2017-11-23 2019-05-23 Forschungszentrum Jülich GmbH Verfahren zur Quantifizierung von Proteinaggregaten einer Proteinfehlfaltungserkrankung in einer Probe
DE102021121435A1 (de) 2021-08-18 2023-02-23 Priavoid Gmbh Aß-BINDENDE SUBSTANZEN
AU2024325238A1 (en) * 2023-08-16 2026-03-05 LVIS-Regain LP Compositions and methods for prophylaxis and/or treatment of amyloid b peptide proteinopenia in alzheimer's and other diseases

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0815134B1 (en) 1995-03-14 2002-06-05 Praecis Pharmaceuticals Incorporated Modulators of amyloid aggregation
US7384910B2 (en) * 1997-10-08 2008-06-10 Castillo Gerardo M Small peptides for the treatment of Alzheimer's disease and other beta-amyloid protein fibrillogenesis disorders
ES2260956T3 (es) 1998-12-18 2006-11-01 The Penn State Research Foundation Ciclacion de peptidos mediada por inteina.
WO2001034631A2 (en) 1999-11-05 2001-05-17 Axonyx, Inc. PEPTIDE ANALOGS AND MIMETICS SUITABLE FOR IN VIVO USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH ABNORMAL PROTEIN FOLDING INTO AMYLOID, AMYLOID-LIKE DEPOSITS OR β-SHEET RICH PATHOLOGICAL PRECURSOR THEREOF
AU1608801A (en) 1999-11-15 2001-05-30 Parker Hughes Institute Diamino platinum (ii) antitumor complexes
DE10117281A1 (de) 2001-04-06 2002-10-24 Inst Molekulare Biotechnologie Peptid zur Diagnose und Therapie der Alzheimer-Demenz
JP5137400B2 (ja) * 2003-06-30 2013-02-06 テル アヴィヴ ユニヴァーシティ フューチャー テクノロジー ディヴェロップメント エル．ピー． アミロイド関連疾患を診断および処置するためのペプチド、それに対する抗体、ならびにその使用方法
GB0503434D0 (en) * 2005-02-18 2005-03-30 Senexis Ltd Amyloid-binding peptides, analogues and uses thereof
DE102005049537B4 (de) 2005-10-17 2010-04-22 Forschungszentrum Karlsruhe Gmbh Verfahren zur Herstellung zyklischer Peptide und Verwendung der derart hergestellten zyklischen Peptide
DE102006015140A1 (de) 2006-03-31 2007-10-11 Philipps-Universität Marburg Heterozyklische Verbindungen mit Wirkung gegen neurodegenerative Erkrankungen
WO2007145589A1 (en) * 2006-06-15 2007-12-21 Per Arvidsson Peptides that are capable of binding to amyloid-beta peptide.
WO2008116293A1 (en) 2007-03-23 2008-10-02 The Governors Of The University Of Alberta Multivalent heterobifunctional polymers and methods of their use
DE102008037564A1 (de) * 2008-11-19 2010-05-20 Forschungszentrum Jülich GmbH Zusammensetzung zur Herstellung von anti-Amyloid beta-Peptid-Antikörpern mit D-Peptiden
DE102010019336A1 (de) 2010-05-05 2011-11-10 Forschungszentrum Jülich GmbH Mittel zur Behandlung der Alzheimerschen Demenz
DE102010017130B4 (de) 2010-05-28 2018-11-29 Forschungszentrum Jülich GmbH Hybrid-Verbindung, deren Verwendung und Verfahren zu deren Herstellung
WO2013021353A1 (en) 2011-08-11 2013-02-14 Bar-Ilan University Surface modified proteinaceous spherical particles and uses thereof
DE102012102999A1 (de) 2012-04-05 2013-10-10 Forschungszentrum Jülich GmbH Verfahren zur Behandlung von Blut, Blutprodukten und Organen
JP6434903B2 (ja) 2012-04-05 2018-12-05 フォルシュングスツェントルム ユーリッヒ ゲゼルシャフト ミット ベシュレンクテル ハフツングＦｏｒｓｃｈｕｎｇｓｚｅｎｔｒｕｍ Ｊｕｅｌｉｃｈ ＧｍｂＨ 多価アミロイドβに結合するＤ−ペプチド含有ポリマー及びその使用
CN108926749A (zh) 2012-04-05 2018-12-04 于利希研究中心有限公司 处理血液、血液产品和器官的方法
DE102012102998B4 (de) 2012-04-05 2013-12-05 Forschungszentrum Jülich GmbH Polymere, enthaltend multivalente Amyloid-Beta-bindende D-Peptide und deren Verwendung
US10030056B2 (en) 2013-04-30 2018-07-24 Forschungszentrum Juelich Gmbh Agents for preventing and treating HIV and other viral infections

Also Published As

Publication number Publication date
ES2953883T3 (es) 2023-11-16
US11274125B2 (en) 2022-03-15
EP3747454B1 (de) 2023-06-07
EP3747454B9 (de) 2023-10-04
ES2818929T3 (es) 2021-04-14
US20160297852A1 (en) 2016-10-13
CN105745219B (zh) 2020-10-09
US20200002379A9 (en) 2020-01-02
EP3049099A1 (de) 2016-08-03
CN105745219A (zh) 2016-07-06
JP2016539911A (ja) 2016-12-22
US10995118B2 (en) 2021-05-04
DK3049099T3 (da) 2020-09-21
EP3747454C0 (de) 2023-06-07
WO2015043567A1 (de) 2015-04-02
EP3747454A1 (de) 2020-12-09
US20200317734A1 (en) 2020-10-08
EP3049099B1 (de) 2020-06-17

Similar Documents

Publication Publication Date Title
US11274125B2 (en) Amyloid-beta-binding peptides and the use thereof for the treatment and diagnosis of Alzheimer's disease
JP6861684B2 (ja) 多価アミロイドβに結合するＤ−ペプチド含有ポリマー及びその使用
JP6997160B2 (ja) 血液、血液生産物及び器官を処置する方法
JP6611858B2 (ja) Ｄ３から誘導されたｄ−エナンチオマーの新規ペプチド及びその使用
JP2020023510A (ja) アミロイドベータ結合性環状ペプチドおよびその使用
JP2018512410A (ja) アミロイドβ特異的結合ペプチドならびにアルツハイマー型認知症の治療および診断のためのその使用
JP6714610B2 (ja) アルツハイマー型認知症の治療および／または診断のための特定のａ−ベータ種に結合するペプチド

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170809

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20171213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180801

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181030

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20181116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190403

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190605

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191213

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200108

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200204

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200210

R150 Certificate of patent or registration of utility model

Ref document number: 6660877

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250